SCHEMBL4771297

SCHEMBL4771297

Cc1ccc(Cl)cc1N1CCN(C(c2ccc(Cl)cc2Cl)C(N)C=O)CC1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.46
ALDH1A1 P00352 3/20 0.45
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
MCOLN3 Q8TDD5 1/20 0.44
LMNA P02545 4/20 0.42
TSHR P16473 2/20 0.42
USP2 O75604 2/20 0.41
MAPT P10636 4/20 0.40
HTT P42858 2/20 0.40
THRB P10828 1/20 0.40
ATM Q13315 1/20 0.40
POLB P06746 3/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
NR1H4 Q96RI1 1/20 0.39
KDM4E B2RXH2 1/20 0.39
RPS6KB1 P23443 1/20 0.39
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4776952 0.88 LMNA (0.46) NPSR1ALDH1A1MEN1KMT2AMCOLN3
SCHEMBL4778604 0.86 NPSR1 (0.46) NPSR1ALDH1A1MEN1KMT2AMCOLN3
SCHEMBL4776587 0.81 KDM4E (0.45) NPSR1ALDH1A1MEN1KMT2AMCOLN3
SCHEMBL4770304 0.81 NPSR1 (0.39) NPSR1ALDH1A1MEN1KMT2AMCOLN3
SCHEMBL4779189 0.81 NPSR1 (0.43) NPSR1ALDH1A1MEN1KMT2AMCOLN3
SCHEMBL4776309 0.80 NPSR1 (0.42) NPSR1ALDH1A1MEN1KMT2AMCOLN3
SCHEMBL4773595 0.79 ALDH1A1 (0.43) NPSR1ALDH1A1MEN1KMT2AMCOLN3
SCHEMBL4778352 0.78 ALDH1A1 (0.40) NPSR1ALDH1A1MEN1KMT2ALMNA
SCHEMBL4774991 0.77 LMNA (0.39) NPSR1ALDH1A1LMNAMAPTHTT
SCHEMBL4773571 0.75 CNR1 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP disclosed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO disclosed